Bill Sweet

"Instead of paying tax on dividends you pay capital gains tax on BOX when you sell the fund... It's considered a 1256 contract... 60% long-term, 40% short-term regardless of the holding period." Traditional cash instruments (like T-Bills or HYSA) generate ordinary income, which is taxed at the highest marginal rate. BOXX utilizes options strategies to replicate the risk-free rate but delivers returns via price appreciation. For high-net-worth investors in taxable accounts, the tax-equivalent yield of BOXX is significantly higher than standard money markets because it leverages the 60/40 tax rule and defers taxes until sale. LONG as a cash-management tool for high-tax bracket investors. Regulatory risk (IRS closing the loophole), counterparty risk in the options market (though collateralized), or rising interest rates affecting the spread mechanics.

"Liquidity premium, I think, is what you're paying, what you're getting, right, in most of these funds [Private Equity]... You can look at micro cap, you can look at smaller caps. You just don't have to go into these private vehicles and take in all the cost." Private Equity returns are often correlated with size and value factors found in public markets. Investors seeking high growth or "private-like" returns should buy public Micro Caps (IWC) or Small Caps (IWM) instead of locking money into illiquid PE funds. This avoids the "2 and 20" fee structure, K-1 tax headaches, and 10-year lockups while targeting similar underlying business dynamics. LONG public small/micro caps as a liquid proxy for Private Equity exposure. Small caps are highly volatile and sensitive to interest rates; they lack the "volatility laundering" (smoothing) effect of private valuations.

"Liquidity premium, I think, is what you're paying, what you're getting, right, in most of these funds [Private Equity]... You can look at micro cap, you can look at smaller caps. You just don't have to go into these private vehicles and take in all the cost." Private Equity returns are often correlated with size and value factors found in public markets. Investors seeking high growth or "private-like" returns should buy public Micro Caps (IWC) or Small Caps (IWM) instead of locking money into illiquid PE funds. This avoids the "2 and 20" fee structure, K-1 tax headaches, and 10-year lockups while targeting similar underlying business dynamics. LONG public small/micro caps as a liquid proxy for Private Equity exposure. Small caps are highly volatile and sensitive to interest rates; they lack the "volatility laundering" (smoothing) effect of private valuations.

High-income assets (REITs, Bonds) generate ordinary income, which is taxed at the highest marginal rates (e.g., 35%). Asset *Location* is a free lunch. By placing these assets in tax-deferred accounts (IRAs/401ks) and keeping capital-gain efficient assets (Stocks/ETFs) in taxable accounts, you arbitrage the tax code to increase net returns. LONG these assets specifically within tax-qualified accounts. Future tax legislation changes that alter the treatment of qualified dividends vs. ordinary income.

"I have watched our health insurance increase at roughly 8% a year for the last almost 10 years... The average premium for a health insurance plan across the United States... is $27,000." Sweet notes that these margins "are paying people's jobs" and the system is entrenched despite regulation. Persistent 8% annual inflation in premiums translates directly to compounding revenue growth for major health insurers and providers. The inability to fix the system implies pricing power remains with the incumbents. LONG Healthcare sector and major insurers who are passing these costs on to employers/consumers. Regulatory intervention or a complete overhaul of the US healthcare system (though the speakers deem this unlikely).

"I have watched our health insurance increase at roughly 8% a year for the last almost 10 years... The average premium for a health insurance plan across the United States... is $27,000." Sweet notes that these margins "are paying people's jobs" and the system is entrenched despite regulation. Persistent 8% annual inflation in premiums translates directly to compounding revenue growth for major health insurers and providers. The inability to fix the system implies pricing power remains with the incumbents. LONG Healthcare sector and major insurers who are passing these costs on to employers/consumers. Regulatory intervention or a complete overhaul of the US healthcare system (though the speakers deem this unlikely).